Loading...
 
Back to the list
Mediterr J Rheumatol 2019;30(1):7-15
Article Links
Cerebrovascular Events in Systemic Lupus Erythematosus: Diagnosis and Management
Dionysis Nikolopoulos1,2, Antonis Fanouriakis1, Dimitrios T. Boumpas1,2,3
Authors Information

1Rheumatology and Clinical Immunology Unit, 4th Department of Medicine, “Attikon” University Hospital, Athens, Greece

2Laboratory of Immune Regulation and Tolerance, Autoimmunity and Inflammation, Biomedical Research Foundation of the Academy of Athens, Athens, Greece

3Medical School, University of Cyprus, Nicosia, Cyprus

Keywords: Cerebrovascular Events, Systemic Lupus Erythematosus, Brain Imaging, Drug Therapy
References
  1. Fanouriakis A, Boumpas DT, Bertsias GK. Pathogenesis and treatment of CNS lupus. Curr Opin Rheumatol 2013;25:577-83. [https://doi.org/10.1097/BOR.0b013e328363eaf1] [PMID: 23836074]
  2. Bertsias GK, Boumpas DT. Pathogenesis, diagnosis and management of neuropsychiatric SLE manifestations. Nat Rev Rheumatol 2010;6:358-67. [https://doi.org/10.1038/nrrheum.2010.62] [PMID: 20458332]
  3. Unterman A, Nolte JE, Boaz M, Abady M, Shoenfeld Y, Zandman-Goddard G. Neuropsychiatric syndromes in systemic lupus erythematosus: a meta-analysis. Semin Arthritis Rheum 2011;41:1-11. [https://doi.org/10.1016/j.semarthrit.2010.08.001] [PMID: 20965549]
  4. Bertsias GK, Ioannidis JP, Aringer M, Bollen E, Bombardieri S, Bruce IN, et al. EULAR recommendations for the management of systemic lupus erythematosus with neuropsychiatric manifestations: report of a task force of the EULAR standing committee for clinical affairs. Ann Rheum Dis 2010;69:2074-82. [https://doi.org/10.1136/ard.2010.130476] [PMID: 20724309]
  5. Fanouriakis A, Pamfil C, Rednic S, Sidiropoulos P, Bertsias G, Boumpas DT. Is it primary neuropsychiatric systemic lupus erythematosus? Performance of existing attribution models using physician judgment as the gold standard. Clin Exp Rheumatol 2016;34:910-7. [PMID: 27463840]
  6. Hanly JG, Li Q, Su L, Urowitz MB, Gordon C, Bae SC, et al. Cerebrovascular Events in Systemic Lupus Erythematosus. Arthritis Care Res (Hoboken) 2018;70:1478-87. [https://doi.org/10.1002/acr.23509] [PMID: 29316357] [PMCID: PMC6033693]
  7. Cervera R, Khamashta MA, Font J, Sebastiani GD, Gil A, Lavilla P, et al. Morbidity and mortality in systemic lupus erythematosus during a 10-year period: a comparison of early and late manifestations in a cohort of 1,000 patients. Medicine (Baltimore) 2003;82:299-308. [https://doi.org/10.1097/01.md.0000091181.93122.55] [PMID: 14530779]
  8. Saadatnia M, Sayed-Bonakdar Z, Mohammad-Sharifi G, Sarrami AH. The necessity of stroke prevention in patients with systemic lupus erythematosus. J Res Med Sci 2012;17: 894-5. [PMID: 23826023] [PMCID: PMC3697221]
  9. Arkema EV, Svenungsson E, Von Euler M, Sjowall C, Simard JF. Stroke in systemic lupus erythematosus: a Swedish population-based cohort study. Ann Rheum Dis 2017;76: 1544-9. [https://doi.org/10.1136/annrheumdis-2016-210973] [PMID: 28400384]
  10. Pons-Estel GJ, Andreoli L, Scanzi F, Cervera R, Tincani A. The antiphospholipid syndrome in patients with systemic lupus erythematosus. J Autoimmun 2017;76:10-20. [https://doi.org/10.1016/j.jaut.2016.10.004] [PMID: 27776934]
  11. Schoenfeld SR, Kasturi S, Costenbader KH. The epidemiology of atherosclerotic cardiovascular disease among patients with SLE: a systematic review. Semin Arthritis Rheum 2013;43:77-95. [https://doi.org/10.1016/j.semarthrit.2012.12.002] [PMID: 23422269]
  12. Mok CC, Ho LY, To CH. Annual incidence and standardized incidence ratio of cerebrovascular accidents in patients with systemic lupus erythematosus. Scand J Rheumatol 2009;38:362-8. [https://doi.org/10.1080/03009740902776927] [PMID: 19296403]
  13. Barbhaiya M, Feldman CH, Guan H, Chen SK, Fischer MA, Solomon DH, et al. Racial/ethnic variation in stroke rates and risks among patients with systemic lupus erythematosus. Semin Arthritis Rheum 2018;S0049-0172(18)30059-3. [https://doi.org/10.1016/j.semarthrit.2018.07.012] [PMID: 30205982] [PMCID: PMC6377855]
  14. Chiu CC, Huang CC, Chan WL, Chung CM, Huang PH, Lin SJ, et al. Increased risk of ischemic stroke in patients with systemic lupus erythematosus: a nationwide population-based study. Intern Med 2012;51:17-21. [PMID: 22214618]
  15. Mikdashi J, Handwerger B, Langenberg P, Miller M, Kittner S. Baseline disease activity, hyperlipidemia, and hypertension are predictive factors for ischemic stroke and stroke severity in systemic lupus erythematosus. Stroke 2007;38:281-5. [https://doi.org/10.1161/01.STR.0000254476.05620.14] [PMID: 17218611]
  16. Holmqvist M, Simard JF, Asplund K, Arkema EV. Stroke in systemic lupus erythematosus: a meta-analysis of population-based cohort studies. RMD Open 2015;1:e000168. [https://doi.org/10.1136/rmdopen-2015-000168] [PMID: 26719816] [PMCID: PMC4692049]
  17. Ward MM. Premature morbidity from cardiovascular and cerebrovascular diseases in women with systemic lupus erythematosus. Arthritis Rheum 1999;42:338-46. [https://doi.org/10.1002/1529-0131(199902)42:2%3C338::AID-ANR17%3E3.0.CO;2-U] [PMID: 10025929]
  18. Maynard JW, Fang H, Petri M. Low socioeconomic status is associated with cardiovascular risk factors and outcomes in systemic lupus erythematosus. J Rheumatol 2012;39:777-83. [https://doi.org/10.3899/jrheum.110724] [PMID: 22382345] [PMCID: PMC3597116]
  19. Shaharir SS, Kadir WDA, Nordin F, Bakar FA, Ting MWH, Jamil A, et al. Systemic lupus erythematosus among male patients in Malaysia: how are we different from other geographical regions? Lupus 2018;28(1):137-44. [https://doi.org/10.1177/0961203318812676]
  20. Tektonidou MG, Lewandowski LB, Hu J, Dasgupta A, Ward MM. Survival in adults and children with systemic lupus erythematosus: a systematic review and Bayesian meta-analysis of studies from 1950 to 2016. Ann Rheum Dis 2017;76: 2009-16. [https://doi.org/10.1136/annrheumdis-2017-211663] [PMID: 28794077]
  21. Bjornadal L, Yin L, Granath F, Klareskog L, Ekbom A. Cardiovascular disease a hazard despite improved prognosis in patients with systemic lupus erythematosus: results from a Swedish population based study 1964-95. J Rheumatol 2004;31:713-9. [PMID: 15088296]
  22. Gergianaki I, Fanouriakis A, Repa A, Tzanakakis M, Adamichou C, Pompieri A, et al. Epidemiology and burden of systemic lupus erythematosus in a Southern European population: data from the community-based lupus registry of Crete, Greece. Ann Rheum Dis 2017;76:1992-2000. [https://doi.org/10.1136/annrheumdis-2017-211206] [PMID: 28780511]
  23. Pamfil C, Fanouriakis A, Damian L, Rinzis M, Sidiropoulos P, Tsivgoulis G, et al. EULAR recommendations for neuropsychiatric systemic lupus erythematosus vs usual care: results from two European centres. Rheumatology (Oxford) 2015;54:1270-8. [https://doi.org/10.1093/rheumatology/keu482] [PMID: 25638807]
  24. Ferro JM, Massaro AR, Mas JL. Aetiological diagnosis of ischaemic stroke in young adults. Lancet Neurol 2010;9:1085-96. [https://doi.org/10.1016/S1474-4422(10)70251-9] [PMID: 20965437]
  25. Putaala J, Metso AJ, Metso TM, Konkola N, Kraemer Y, Haapaniemi E, et al. Analysis of 1008 consecutive patients aged 15 to 49 with first-ever ischemic stroke: the Helsinki young stroke registry. Stroke 2009;40:1195-203. [https://doi.org/10.1161/STROKEAHA.108.529883]
  26. Khan S, Cloud GC, Kerry S, Markus HS. Imaging of vertebral artery stenosis: a systematic review. J Neurol Neurosurg Psychiatry 2007;78:1218-25. [https://doi.org/10.1136/jnnp.2006.111716] [PMID: 17287234] [PMCID: PMC2117584]
  27. Wardlaw JM, Chappell FM, Best JJ, Wartolowska K, Berry E, Research NHS, et al. Non-invasive imaging compared with intra-arterial angiography in the diagnosis of symptomatic carotid stenosis: a meta-analysis. Lancet 2006;367:1503-12. [https://doi.org/10.1016/S0140-6736(06)68650-9] [PMID: 16679163]
  28. de Bruijn SF, Agema WR, Lammers GJ, van der Wall EE, Wolterbeek R, Holman ER, et al. Transesophageal echocardiography is superior to transthoracic echocardiography in management of patients of any age with transient ischemic attack or stroke. Stroke 2006;37:2531-4. [https://doi.org/10.1161/01.STR.0000241064.46659.69] [PMID: 16946152]
  29. Liao J, Khalid Z, Scallan C, Morillo C, O'Donnell M. Noninvasive cardiac monitoring for detecting paroxysmal atrial fibrillation or flutter after acute ischemic stroke: a systematic review. Stroke 2007;38:2935-40. [https://doi.org/10.1161/STROKEAHA.106.478685] [PMID: 17901394]
  30. Miyakis S, Lockshin MD, Atsumi T, Branch DW, Brey RL, Cervera R, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 2006;4:295-306. [https://doi.org/10.1111/j.1538-7836.2006.01753.x] [PMID: 16420554]
  31. Sciascia S, Sanna G, Khamashta MA, Cuadrado MJ, Erkan D, Andreoli L, et al. The estimated frequency of antiphospholipid antibodies in young adults with cerebrovascular events: a systematic review. Ann Rheum Dis 2015;74:2028-33. [https://doi.org/10.1136/annrheumdis-2014-205663] [PMID: 24942381]
  32. Bombardier C, Gladman DD, Urowitz MB, Caron D, Chang CH. Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE. Arthritis Rheum 1992;35:630-40. [PMID: 1599520]
  33. Govoni M, Bombardieri S, Bortoluzzi A, Caniatti L, Casu C, Conti F, et al. Factors and comorbidities associated with first neuropsychiatric event in systemic lupus erythematosus: does a risk profile exist? A large multicentre retrospective cross-sectional study on 959 Italian patients. Rheumatology (Oxford) 2012;51:157-68. [https://doi.org/10.1093/rheumatology/ker310] [PMID: 22075066]
  34. Roman MJ, Shanker BA, Davis A, Lockshin MD, Sammaritano L, Simantov R, et al. Prevalence and correlates of accelerated atherosclerosis in systemic lupus erythematosus. N Engl J Med 2003;349:2399-406. [https://doi.org/10.1056/NEJMoa035471] [PMID: 14681505]
  35. de Amorim LC, Maia FM, Rodrigues CE. Stroke in systemic lupus erythematosus and antiphospholipid syndrome: risk factors, clinical manifestations, neuroimaging, and treatment. Lupus 2017;26:529-36. [https://doi.org/10.1177/0961203316688784] [PMID: 28394226]
  36. Wardlaw JM, Valdes Hernandez MC, Munoz-Maniega S. What are white matter hyperintensities made of? Relevance to vascular cognitive impairment. J Am Heart Assoc 2015;4:001140. [https://doi.org/10.1161/JAHA.114.001140] [PMID: 26104658] [PMCID: PMC4599520]
  37. Rockwood K, Song X, MacKnight C, Bergman H, Hogan DB, McDowell I, et al. A global clinical measure of fitness and frailty in elderly people. CMAJ 2005;173:489-95. [https://doi.org/10.1503/cmaj.050051]  [PMID: 16129869] [PMCID: PMC1188185]
  38. Dufouil C, de Kersaint-Gilly A, Besancon V, Levy C, Auffray E, Brunnereau L, et al. Longitudinal study of blood pressure and white matter hyperintensities: the EVA MRI Cohort. Neurology 2001;56:921-6. [PMID: 11294930]
  39. Ferguson SC, Blane A, Perros P, McCrimmon RJ, Best JJ, Wardlaw J, et al. Cognitive ability and brain structure in type 1 diabetes: relation to microangiopathy and preceding severe hypoglycemia. Diabetes 2003;52:149-56. [PMID: 12502506]
  40. Gons RA, van Norden AG, de Laat KF, van Oudheusden LJ, van Uden IW, Zwiers MP, et al. Cigarette smoking is associated with reduced microstructural integrity of cerebral white matter. Brain 2011;134:2116-24. [https://doi.org/10.1093/brain/awr145] [PMID: 21705426]
  41. Hopkins RO, Beck CJ, Burnett DL, Weaver LK, Victoroff J, Bigler ED. Prevalence of white matter hyperintensities in a young healthy population. J Neuroimaging 2006;16:243-51. [https://doi.org/10.1111/j.1552-6569.2006.00047.x] [PMID: 16808826]
  42. Cohen D, Rijnink EC, Nabuurs RJ, Steup-Beekman GM, Versluis MJ, Emmer BJ, et al. Brain histopathology in patients with systemic lupus erythematosus: identification of lesions associated with clinical neuropsychiatric lupus syndromes and the role of complement. Rheumatology (Oxford) 2017;56:77-86. [https://doi.org/10.1093/rheumatology/kew341] [PMID: 28028157]
  43. Cavallaro M, Barbaro U, Caragliano A, Longo M, Cicero G, Granata F, Racchiusa S. Stroke and Systemic Lupus Erythematosus: A Review. EMJ Rheumatol 2018;5:100-07.
  44. Luyendijk J, Steens SC, Ouwendijk WJ, Steup-Beekman GM, Bollen EL, van der Grond J, et al. Neuropsychiatric systemic lupus erythematosus: lessons learned from magnetic resonance imaging. Arthritis Rheum 2011;63:722-72. [https://doi.org/10.1002/art.30157] [PMID: 21360502]
  45. Toledano P, Sarbu N, Espinosa G, Bargallo N, Cervera R. Neuropsychiatric systemic lupus erythematosus: magnetic resonance imaging findings and correlation with clinical and immunological features. Autoimmun Rev 2013;12:1166-70. [https://doi.org/10.1016/j.autrev.2013.07.004] [PMID: 23851139]
  46. Appenzeller S, Vasconcelos Faria A, Li LM, Costallat LT, Cendes F. Quantitative magnetic resonance imaging analyses and clinical significance of hyperintense white matter lesions in systemic lupus erythematosus patients. Ann Neurol 2008;64:635-43. [https://doi.org/10.1002/ana.21483] [PMID: 19107986]
  47. Debette S, Markus HS. The clinical importance of white matter hyperintensities on brain magnetic resonance imaging: systematic review and meta-analysis. BMJ 2010;341:c3666. [https://doi.org/10.1136/bmj.c3666] [PMID: 20660506] [PMCID: PMC2910261]
  48. Ay H, Arsava EM, Rosand J, Furie KL, Singhal AB, Schaefer PW, et al. Severity of leukoaraiosis and susceptibility to infarct growth in acute stroke. Stroke 2008;39:1409-13. [https://doi.org/10.1161/STROKEAHA.107.501932] [PMID: 18340093]
  49. Piepoli MF, Hoes AW, Agewall S, Albus C, Brotons C, Catapano AL, et al. 2016 European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts)Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). Eur Heart J 2016;37: 2315-81. [https://doi.org/10.1093/eurheartj/ehw106] [PMID: 27222591] [PMCID: PMC4986030]
  50. Ugarte-Gil MF, Wojdyla D, Pons-Estel GJ, Pons-Estel BA, Alarcon GS, Gladel. Remission or low disease activity as a target in systemic lupus erythematosus. Ann Rheum Dis 2019;78:e3. [https://doi.org/10.1136/annrheumdis-2017-212876] [PMID: 29311147]
  51. Teixeira V, Lam RS. Novel Insights in Systemic Lupus Erythematosus and Atherosclerosis. Front Med (Lausanne) 2017;4:262. [https://doi.org/10.3389/fmed.2017.00262] [PMID: 29435447] [PMCID: PMC5796914]
  52. Artola RT, Mihos CG, Santana O. Effects of Statin Therapy in Patients with Systemic Lupus Erythematosus. South Med J 2016;109:705-11. [https://doi.org/10.14423/SMJ.0000000000000561] [PMID: 27812716]
  53. Watanabe T, Oku K, Amengual O, Hisada R, Ohmura K, Nakagawa I, et al. Effects of statins on thrombosis development in patients with systemic lupus erythematosus and antiphospholipid antibodies. Lupus 2018;27:225-34. [https://doi.org/10.1177/0961203317716787] [PMID: 28659045]
  54. Jorge AM, Lu N, Keller SF, Rai SK, Zhang Y, Choi HK. The Effect of Statin Use on Mortality in Systemic Autoimmune Rheumatic Diseases. J Rheumatol 2018;45:1689-95. [https://doi.org/10.3899/jrheum.171389] [PMID: 30173155] [PMCID: PMC6289699]
  55. Sahebkar A, Rathouska J, Derosa G, Maffioli P, Nachtigal P. Statin impact on disease activity and C-reactive protein concentrations in systemic lupus erythematosus patients: A systematic review and meta-analysis of controlled trials. Autoimmun Rev 2016;15:344-53. [https://doi.org/10.1016/j.autrev.2015.12.007] [PMID: 26747436]
  56. Vera-Lastra O, Mendez-Flores S, Cruz-Dominguez MP, Medina G, Calderon-Aranda E, Jara LJ. Effect of ezetimibe plus pravastatin on endothelial dysfunction in patients with systemic lupus erythematosus. Lupus 2016;25:741-8. [https://doi.org/10.1177/0961203316631631] [PMID: 26923285]
  57. Petri MA, Kiani AN, Post W, Christopher-Stine L, Magder LS. Lupus Atherosclerosis Prevention Study (LAPS). Ann Rheum Dis 2011;70:760-5. [https://doi.org/10.1136/ard.2010.136762] [PMID: 21177297] 
  58. Schanberg LE, Sandborg C, Barnhart HX, Ardoin SP, Yow E, Evans GW, et al. Use of atorvastatin in systemic lupus erythematosus in children and adolescents. Arthritis Rheum 2012;64:285-96. [https://doi.org/10.1002/art.30645] [PMID: 22031171] [PMCID: PMC4074430]
  59. Bertsias G, Ioannidis JP, Boletis J, Bombardieri S, Cervera R, Dostal C, et al. EULAR recommendations for the management of systemic lupus erythematosus. Report of a Task Force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics. Ann Rheum Dis 2008;67:195-205. [https://doi.org/10.1136/ard.2007.070367] [PMID: 17504841]
  60. Groot N, de Graeff N, Marks SD, Brogan P, Avcin T, Bader-Meunier B, et al. European evidence-based recommendations for the diagnosis and treatment of childhood-onset lupus nephritis: the SHARE initiative. Ann Rheum Dis 2017;76:1965-73. [https://doi.org/10.1136/annrheumdis-2017-211898] [PMID: 28877866]
  61. Arnaud L, Mathian A, Ruffatti A, Erkan D, Tektonidou M, Cervera R, et al. Efficacy of aspirin for the primary prevention of thrombosis in patients with antiphospholipid antibodies: an international and collaborative meta-analysis. Autoimmun Rev 2014;13: 281-91. [https://doi.org/10.1016/j.autrev.2013.10.014] [PMID: 24189281]
  62. Gaziano JM, Brotons C, Coppolecchia R, Cricelli C, Darius H, Gorelick PB, et al. Use of aspirin to reduce risk of initial vascular events in patients at moderate risk of cardiovascular disease (ARRIVE): a randomised, double-blind, placebo-controlled trial. Lancet 2018;392:1036-46. [https://doi.org/10.1016/S0140-6736(18)31924-X] [PMID: 30158069]
  63. Group ASC, Bowman L, Mafham M, Wallendszus K, Stevens W, Buck G, et al. Effects of Aspirin for Primary Prevention in Persons with Diabetes Mellitus. N Engl J Med 2018;379: 1529-39. [https://doi.org/10.1056/NEJMoa1804988] [PMID: 30146931]
  64. Ruiz-Irastorza G, Ramos-Casals M, Brito-Zeron P, Khamashta MA. Clinical efficacy and side effects of antimalarials in systemic lupus erythematosus: a systematic review. Ann Rheum Dis 2010;69:20-8. [https://doi.org/10.1136/ard.2008.101766] [PMID: 19103632]
  65. Petri M. Hydroxychloroquine use in the Baltimore Lupus Cohort: effects on lipids, glucose and thrombosis. Lupus 1996;5 Suppl 1:S16-22. [PMID: 8803905]
  66. Ruiz-Irastorza G, Egurbide MV, Pijoan JI, Garmendia M, Villar I, Martinez-Berriotxoa A, et al. Effect of antimalarials on thrombosis and survival in patients with systemic lupus erythematosus. Lupus 2006;15:577-83. [https://doi.org/10.1177/0961203306071872] [PMID: 17080912]
  67. Tektonidou MG, Laskari K, Panagiotakos DB, Moutsopoulos HM. Risk factors for thrombosis and primary thrombosis prevention in patients with systemic lupus erythematosus with or without antiphospholipid antibodies. Arthritis Rheum 2009;61:29-36. [https://doi.org/10.1002/art.24232] [PMID: 19116963]
  68. Fasano S, Pierro L, Pantano I, Iudici M, Valentini G. Longterm Hydroxychloroquine Therapy and Low-dose Aspirin May Have an Additive Effectiveness in the Primary Prevention of Cardiovascular Events in Patients with Systemic Lupus Erythematosus. J Rheumatol 2017;44:1032-8. [https://doi.org/10.3899/jrheum.161351] [PMID: 28507183]
  69. Camara-Lemarroy CR, Infante-Valenzuela A, Andrade-Vazquez CJ, Enriquez-Noyola RV, Garcia-Valadez EA, Gongora-Rivera F. Successful intravenous thrombolysis in a patient with antiphospholipid syndrome, acute ischemic stroke and severe thrombocytopenia. Blood Coagul Fibrinolysis 2016;27:354-6. [https://doi.org/10.3389/fneur.2018.01001] [PMID: 30534110] [PMCID: PMC6275383]
  70. Chen X, Xu G. Intravenous thrombolysis in SLE-related stroke: a case report and literature review. Neurol Sci 2018;39:155-9. [https://doi.org/10.1007/s10072-017-3158-4] [PMID: 29116545]
  71. Schreiber K, Sciascia S, de Groot PG, Devreese K, Jacobsen S, Ruiz-Irastorza G, et al. Antiphospholipid syndrome. Nat Rev Dis Primers 2018;4:17103. [https://doi.org/10.1038/nrdp.2017.103] [PMID: 29321641]